SCHEMBL17829985

SCHEMBL17829985

CCCCCNc1nc(N)nc2c(C)csc12

nearest known ligand 0.51

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 17/20 0.51
PRKCI P41743 3/20 0.48
TLR7 Q9NYK1 8/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17829979 0.96 TLR8 (0.52) TLR8PRKCITLR7
SCHEMBL7687751 0.84 PRKCI (0.45) TLR8PRKCITLR7
SCHEMBL7677206 0.83 PRKCI (0.44) TLR8PRKCI
SCHEMBL7677137 0.83 PRKCI (0.44) TLR8PRKCI
SCHEMBL7680936 0.83 PRKCI (0.44) TLR8PRKCI
SCHEMBL22448322 0.81 PRKCI (0.43) TLR8PRKCITLR7
SCHEMBL7683034 0.80 PRKCI (0.46) TLR8PRKCITLR7
SCHEMBL7678778 0.79 PRKCI (0.41) TLR8PRKCI
SCHEMBL22448319 0.78 TLR8 (0.42) TLR8PRKCITLR7
SCHEMBL7685780 0.78 PRKCI (0.41) PRKCI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10822347-B2 Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections Janssen Sciences Ireland Unlimited Company (IE) 2020-11-03 US disclosed
EP-3404031-B1 THIENO[3,2-D]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2020-09-23 EP disclosed
US-20190330227-A1 THIENO[3,2-D]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS JANSSEN SCIENCES IRELAND UC (IE) 2019-10-31 US disclosed
US-10316043-B2 Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections Janssen Sciences Ireland Unlimited Company (IE) 2019-06-11 US disclosed
US-20170298079-A1 THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS JANSSEN SCIENCES IRELAND UC (IE) 2017-10-19 US disclosed
US-20170298079-A1 THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS JANSSEN SCIENCES IRELAND UC (IE) 2017-10-19 US disclosed
US-9556199-B2 Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections JANSSEN SCIENCES IRELAND UC (IE) 2017-01-31 US disclosed
US-9556199-B2 Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections JANSSEN SCIENCES IRELAND UC (IE) 2017-01-31 US disclosed
US-20160168164-A1 THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS JANSSEN SCIENCES IRELAND UC (IE) 2016-06-16 US disclosed
US-20160168164-A1 THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS JANSSEN SCIENCES IRELAND UC (IE) 2016-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168164-A1 THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS TYMS, TYMP, UMPS TLR8 1457/4885PRKCI 3542/4885TLR7 766/4885
US-20190330227-A1 THIENO[3,2-D]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS TYMS, TYMP, UMPS TLR8 1457/4885PRKCI 3542/4885TLR7 766/4885
US-20170298079-A1 THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS TYMS, TYMP, UMPS TLR8 1457/4885PRKCI 3542/4885TLR7 766/4885
US-10316043-B2 Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections TYMS, TYMP, UMPS TLR8 1457/4885PRKCI 3542/4885TLR7 766/4885
US-10822347-B2 Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections TYMS, TYMP, UMPS TLR8 1457/4885PRKCI 3542/4885TLR7 766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.